Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
This article explores how genomic features differentiate stable from progressive asymptomatic Waldenström macroglobulinemia and IgM-MGUS, highlighting mutation burdens, specific gene alterations, and aneuploidy as prognostic markers for dis
A large genome-wide analysis identifies multiple genetic loci influencing MPN subtypes and reveals a female-specific variant at CDH22/CD40, enhancing understanding of disease heterogeneity and potential for personalized risk stratification.
A registry analysis in Germany reveals superior remission conversion and progression-free survival with ciltacabtagene autoleucel compared to idecabtagene vicleucel in heavily pretreated multiple myeloma, supporting individualized CAR T the
A large international study identified key prognostic markers affecting survival in advanced-stage mycosis fungoides and Sézary syndrome, enabling risk stratification and guiding clinical management.
Large-cell transformation in mycosis fungoides marks an aggressive disease subset with distinct prognostic groups and poor survival, highlighting the need for tailored treatment and integration into staging systems.
The CLIPI prognostic index refines risk stratification in advanced mycosis fungoides and Sézary syndrome, identifying distinct survival groups to guide personalized treatment decisions and improve outcomes.
This article explores genomic factors influencing response and resistance to pirtobrutinib, a reversible BTK inhibitor, in relapsed/refractory CLL patients previously treated with covalent BTK inhibitors, highlighting clonal mutation dynami
This phase 2 trial reveals that both pentostatin-rituximab and bendamustine-rituximab combinations achieve high response rates exceeding rituximab alone in multiply relapsed or refractory hairy cell leukemia, with potential superiority tren
Recent research identifies three unique biological subtypes of chronic graft-versus-host disease (cGvHD) in children post-hematopoietic cell transplantation, offering potential pathways for tailored treatments and improved outcomes.
Circulating tumor cells (CTCs) serve as an independent prognostic biomarker in transplant-eligible newly diagnosed multiple myeloma patients treated with daratumumab-based quadruplet therapy, predicting progression-free survival and minimal
The phase 3 GEM12 trial compares busulfan-melphalan versus melphalan conditioning in ASCT for newly diagnosed multiple myeloma, showing longer PFS with busulfan-melphalan after intensified VRD induction and consolidation, especially in adva
Glofitamab, a CD20×CD3 T-cell engager, demonstrates promising synergistic effects in combination with chemotherapy and novel immunotherapies, addressing resistance mechanisms in non-Hodgkin lymphoma preclinical models and supporting future
MRD monitoring by RT-qPCR in pediatric AML with KMT2A::MLLT10 fusion identifies patients at high risk despite morphologic remission, informing prognosis and guiding therapy.
A dynamic model predicts individualized risk of major bleeding or death with or without prophylactic platelet transfusion in preterm infants, allowing tailored clinical decisions based on evolving patient status.
The ENRICH trial demonstrates that ibrutinib combined with rituximab significantly improves progression-free survival compared to standard immunochemotherapy in older patients with untreated mantle cell lymphoma, heralding a new chemotherap
A recent study assessed the quality, reliability, and popularity of anemia-related videos on YouTube, revealing moderate variability and highlighting the importance of health professionals’ involvement to ensure accurate online conten
A large cohort study links radiation exposure from pediatric medical imaging to a modest but significant increase in hematologic cancer risk, underlining the need for judicious imaging use in children and adolescents.
Phase 3 trial data demonstrate that ibrutinib-venetoclax therapy achieves superior undetectable measurable residual disease rates and significantly prolonged progression-free survival compared with ibrutinib alone or FCR in chronic lymphocy
A phase 2 trial demonstrates that oral hypomethylating agent ASTX727, with optional donor lymphocyte infusion, shows encouraging disease-free survival and manageable safety after stem-cell transplantation in very high-risk acute myeloid leu
A phase 2 trial demonstrates that oral decitabine and cedazuridine maintenance following hematopoietic stem-cell transplantation may improve disease-free survival in very high-risk AML and MDS patients with manageable safety.
Open language-specific specialty feeds and department pages.